Table 4.
Comparison between Model S and Breast Cancer Surveillance Consortium data for women diagnosed between 1996 and 2009
| Outcome | Model S | BCSC | ||
|---|---|---|---|---|
| ER+ cases | ER- cases | ER+ cases | ER- cases | |
| Probability of screen detection | 51.2% | 35.1% | 65.0% | 48.0% |
| Stage distribution among clinically detected cases *‡ | ||||
| Local | 49.9% | 51.0% | 47.2% | 47.0% |
| Regional | 42.9% | 42.1% | 48/3% | 47.5% |
| Distant | 7.2% | 6.8% | 4.5% | 5.4% |
| Stage distribution among interval cases †‡ | ||||
| Local | 57.5% | 55.5% | 61.9% | 60.6% |
| Regional | 36.8% | 37.9% | 35.6% | 34.7% |
| Distant | 5.7% | 6.7% | 2.5% | 4.7% |
| Stage distribution among screen-detected cases‡ | ||||
| Local | 77.8% | 72.9% | 79.5% | 74.5% |
| Regional | 20.7% | 24.8% | 19.9% | 24.3% |
| Distant | 1.5% | 2.3% | 0.5% | 1.1% |
* Cases detected in the absence of screening. BCSC = Breast Cancer Surveillance Consortium; ER = estrogen receptor.
† Cases missed on the screening exam and symptomatically detected within 12 months after the most recent screening exam.
‡ Distributions may not add up to 100% because of rounding errors.